Vancomycin vs TMP/SMX for MRSA – Not the Final Word

Vancomycin got a bad reputation since the early 90ies when it became clear that it was slow to provide clinical improvement and microbiologic cure in MRSA patients.  It was associated with prolonged bacteremia even when combined with rifampin [1].  And for MSSA, anti-staph penicillins like nafcillin were always the better choice. Then, Continue reading Vancomycin vs TMP/SMX for MRSA – Not the Final Word

No Easy Day: Dose Calculations for Aminoglycosides and Vancomycin

Searching data on antibiotic use in surgery prophylaxis, I came across an article from the Mayo Clinic [1].  The authors mention that approx. 75% of patients that developed surgical site infections did not get proper antibiotic prophylaxis.  Errors were made in (1) selection of the antibiotic, (2) timing of administration, (3) antibiotic Continue reading No Easy Day: Dose Calculations for Aminoglycosides and Vancomycin

Aerosolized Antibiotics & Selling Nebulizers

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive.  Continue reading Aerosolized Antibiotics & Selling Nebulizers